In a two‐part, double‐blind phase II study, this therapy was evaluated in aged 4–8‐years‐old DMD patients, with primary endpoints being changes in dystrophin expression and North Star Ambulatory Assessment score. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.